Janssen Search
Search results
Dexamethasone reduces infusion-related reactions in patients with EGFR-mutated non-small cell lung cancer treated with intravenous RYBREVANT® (amivantamab-vmjw)
Sep 10, 2024 United States Pre-medication regimen showed an infusion-related reaction rate of 22.5 percent with intravenous RYBREVANT ®, a three-fold reduction from 67.4 percent historically seen with standard IRR management SAN DIEGO, CA, September 10, ...
RYBREVANT®▼ (amivantamab) in combination with chemotherapy is the first therapy approved by the European Commission for the first-line treatment of patients with advanced non-small cell lung cancer with activating EGFR exon 20 insertion mutations
Jun 28, 2024 Approval is supported by the Phase 3 PAPILLON study, which showed amivantamab plus chemotherapy significantly reduced the risk of disease progression or death by 60 percent compared to chemotherapy alone 1 BEERSE, BELGIUM (28 June 2024) – ...
About World Without Disease Accelerator
About the World Without Disease Accelerator Our Mission Consistent with Johnson & Johnson’s transformational medical innovation strategy, the mission of the World Without Disease Accelerator (WWDA) is to discover, develop and prepare for the ...
World Neuroscience Innovation Forum
Janssen is a sponsor of the World Neuroscience Innovation Forum on March 27, 2017, in London. The conference will cover the latest in neuroscience research and innovation. The goal of the London Forum is to spark new insights, therapeutic paths and ...
Stopping Type 1 Diabetes Before It Starts
Stopping Type 1 Diabetes Before It Starts Each year, World Diabetes Day is celebrated on November 14, the birthday of Sir Frederick Banting, who co-discovered insulin along with Charles Best in 1922. For nearly a century, insulin has been helping people ...
RYBREVANT® (amivantamab-vmjw) plus standard of care approved in the U.S. as first and only targeted regimen to cut risk of disease progression by more than half in second-line EGFR-mutated advanced lung cancer
Sep 19, 2024 United States Approval based on compelling safety and efficacy from the Phase 3 MARIPOSA-2 study, marking the third new indication for RYBREVANT ® this year, with four indications overall RARITAN, New Jersey (September 19, 2024) – Johnson ...
Pioneering Preventive Medicine
Pioneering Preventive Medicine There is a huge need to prevent illnesses associated with aging. Over the past 100 years, preventive strategies have been very successful in controlling infectious diseases. We believe this success can be broadened to keep ...
Healthy Baby Initiative
Healthy Baby Initiative While childhood disease is often diagnosed a few years after the birth of a child, recent science indicates that some disease root causes may initiate early in life. 1 Pregnancy and early childhood years provide a unique window for ...
Vast Potential Applications
Article Type: Human Microbiome Institute Vast Potential Applications The human genome marked a revolutionary shift in research by providing the scientific community with access to more than 20,000 targets with the potential to impact disease. Today, the ...
Clinical Trials
Clinical Trials What is a Clinical Trial? One method for gaining access to investigational medicines is to enroll in a clinical trial. Clinical trials are scientific studies in which investigational medicines are tested to make sure they are safe and ...